Biotechnology

Coeptis Therapeutics

Coeptis Therapeutics released FY2025 annual earnings on March 19 (EST), actual revenue USD 1.363 M, actual EPS USD -2.814 (forecast EPS USD -3.4)

Coeptis Therapeutics released FY2025 Q4 earnings on March 19 (EST), actual revenue USD 862.05 K, actual EPS USD -0.2924

Coeptis Therapeutics released FY2025 9 Months Earnings on November 14, 2025 (EST), with actual revenue of USD 501 K and EPS of USD -2.7915

Coeptis Therapeutics released FY2025 Q3 earnings on November 14 (EST), actual revenue USD 237.44K, actual EPS USD -0.5773

Coeptis Therapeutics released FY2025 Q2 earnings on August 14 (EST), actual revenue USD 200.68K, actual EPS USD -1.1699

Coeptis Therapeutics released FY2025 Semi-Annual Earnings on August 14 (EST), actual revenue USD 263.56 K, actual EPS USD -2.2357

SNAP Biosciences and Monarch Therapeutics Enter into a Collaboration for Cancer Treatment

Coeptis Therapeutics released FY2025 Q1 earnings on May 14 (EST), actual revenue USD 62.87K, actual EPS USD -0.995

Monteverde & Associates PC Investigating Proposed Merger Between Two Companies

Coeptis Therapeutics Merges with Z Squared

Coeptis Therapeutics Agrees to Merge with Dogecoin Mining Company

Coeptis Therapeutics released FY2024 earnings on April 2, 2025 (EST), actual revenue USD 0, actual EPS USD -5.5493 (forecast EPS USD -5.2)

Coeptis Therapeutics released FY2024 Q4 earnings on April 2, 2025 (EST), actual revenue USD 0 (forecast USD --), actual EPS USD -1.3783 (forecast USD -0.8)

Coeptis Therapeutics Successfully Raises $10 Million in Series A Funding to Advance Cancer Cell Therapy Innovations

Coeptis Therapeutics released FY2024 Q3 earnings on November 13 EST, with actual revenue of USD 0 and actual EPS of USD -0.0435

Coeptis Therapeutics released FY2024 9 Months Earnings on November 13 EST, with actual revenue of USD 0 and EPS of USD -3.3481

Coeptis Therapeutics released FY2024 Semi-Annual Earnings on August 16 (EST) with actual revenue of 0 USD and EPS of -3.3031 USD

Coeptis Therapeutics released FY2024 Q2 earnings on August 16 (EST), actual revenue 0 USD, actual EPS -1.6158 USD (forecast EPS -1.8 USD)

Coeptis Therapeutics released FY2024 Q1 earnings on May 10 (EST) with actual revenue of 0 USD and EPS of -1.6887 USD

Coeptis Therapeutics released FY2023 Q4 earnings on March 26, 2024 (EST): Actual Revenue 0 USD (Forecast 0 USD), Actual EPS -2.2164 USD (Forecast -3.2 USD)

Akanda

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

Agape ATP

Co-Diagnostics

NewGenIvf

Netcapital

Tradr 2X Long QBTS Daily ETF

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Liminatus Pharma

Defiance Daily Target 2X Long RGTI ETF

Ticker Change

代码变更

From 2026.04.27 (EST) changed to ZSQR

ZSQR

COEP

Z Squared has announced the pro rata distribution of Coeptis Holdings shares to its shareholders, effective April 27, 2026. Each shareholder will receive one non-transferable share of Coeptis Holdings for each share of Z Squared held as of January 2, 2026. Additionally, Z Squared's common stock will begin trading on the Nasdaq under the ticker ZSQR on the same date. This announcement follows the previously disclosed business combination with Coeptis Therapeutics Holdings.

TradingView

Z Squared

Coeptis Therapeutics - CW25

Z Squared Provides Details on Pro Rata Distribution and Nasdaq Trading Start

426CVR015TMP

NBSE.ESC

ARKG

LABU

IBBQ

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

Pharmaceutical Technology

Hepion Pharmaceuticals, Inc.

ESC NEUBASE THERAPEUTI

SEELOS THERAPEUTICS INC

Seelos Therapeutics

iShares Biotechnology ETF

Ark Genomic Revolution ETF

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

Invesco Nasdaq Biotechnology ETF

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

SPDR S&P Biotech

ALPS Medical Breakthrough

Seaport ENT

Seaport and Hemab target $180m IPOs as biotech listings accumulate

DTCR

CLOU

Z Squared, Inc. (NASDAQ: ZSQR) has provided additional details regarding its pro rata dividend distribution related to its business combination with Coeptis Therapeutics Holdings, Inc. Shareholders of record on January 2, 2026, will receive one share of Coeptis Holdings, Inc. common stock for each share held. The common stock is expected to begin trading on the Nasdaq Global Market under the ticker symbol "ZSQR" on April 27, 2026. Z Squared operates a vertically integrated computing infrastructure, focusing on efficiency and scalability.

StockTitan

Global X Data Center & Dgtl Infrs ETF

Global X Cloud Computing ETF

Z Squared Provides Additional Information on Previously Disclosed Pro Rata Distribution | ZSQR Stock News

Z Squared Announces Completion of Business Combination with Coeptis Therapeutics and Listing on the Nasdaq Global Market | COEP Stock News

iShares Global Healthcare

Health Care Select Sector SPDR

VG Health

iShares US Medical Devices

iShares US Pharma

Z Squared Announces Completion of Business Combination with Coeptis Therapeutics and Listing on the Nasdaq Global Market | COEP Stock News

CoTec Receives $19.9 Million From Warrant Acceleration | CTHCF Stock News

CoTec Receives $19.9 Million From Warrant Acceleration | CTHCF Stock News

Coeptis Therapeutics(COEP.US)

Z Squared Provides Details on Pro Rata Distribution and Nasdaq Trading Start

Seaport and Hemab target $180m IPOs as biotech listings accumulate

Z Squared Provides Additional Information on Previously Disclosed Pro Rata Distribution | ZSQR Stock News

Z Squared Announces Completion of Business Combination with Coeptis Therapeutics and Listing on the Nasdaq Global Market | COEP Stock News

CoTec Receives $19.9 Million From Warrant Acceleration | CTHCF Stock News

Trending